Betatrophin, Body Mass Index (BMI), Insulin Resistance, Polycystic Ovary Syndrome (PCOS)
Conditions
Keywords
Polycystic ovary syndrome, Betatrophin, adolescents, homeostasis model assessment of insulin resistance
Brief summary
Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder in adolescents and women of reproductive age and is frequently associated with insulin resistance and an increased risk of metabolic complications. The mechanisms underlying these metabolic abnormalities are not fully understood. Betatrophin (angiopoietin-like protein 8, ANGPTL8) is a liver- and adipose tissue-derived protein involved in lipid and glucose metabolism and has been suggested to be associated with insulin resistance and metabolic stress. This study aims to evaluate serum betatrophin levels in adolescents with PCOS compared with age-matched healthy controls. Adolescents with PCOS will also be categorized according to body mass index (BMI) as normal-weight or overweight to investigate the potential influence of body weight. Additionally, the relationships between betatrophin levels and anthropometric parameters, hormonal profiles, and markers of insulin resistance will be examined.
Interventions
OTHERSerum betatrophin levels
Measurement of venous blood serum level of betatrophin by ELISA method. These measurements were performed in all groups (Overweight PCOS, Normal-weight PCOS, and Healthy Controls).
Sponsors
Ankara City Hospital Bilkent
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
16 Years to 23 Years
Healthy volunteers
Yes
Inclusion criteria
* Adolescent females aged 16-23 years * Post-menarche status * Diagnosis of polycystic ovary syndrome (PCOS) according to the Rotterdam criteria (for Groups I and II) * Age-matched healthy females without PCOS for control group (Group III). * Ability and willingness to provide informed consent/assent * Willingness to comply with study procedures and blood sample collection
Exclusion criteria
* Cardiovascular diseases including hypertension * Type 1 or type 2 diabetes mellitus * Morbid obesity * Primary adrenal insufficiency * Uterine fibroids * Thyroid dysfunctions including Hashimoto thyroiditis and Grave's disease * Hepatic dysfunctions * Renal insufficiency * Genetic disorders in chromosome constitution or karyotype analysis including monosomy X, trisomy X and gene mutations as BMP15, FMR I, POFIB, and GDF9 * Neurologic diseases * Psychiatric disorders * Autoimmune diseases or syndromes including Addison's disease, autoimmune syndromes, scleroderma, Sjogren's syndrome, myasthenia gravis, inflammatory bowel diseases, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and familial Mediterranean fever * History of any malignancy * History of exposure to chemotherapeutic agents or radiotherapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum betatrophin levels | Single measurement at baseline | picogram/milliliter |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Body mass index | Single measurement at baseline | kg/m² |
| Homeostatic Model Assessment for Insulin Resistance | Single measurement at baseline | HOMA-IR was calculated using the formula: (Fasting insulin \[µIU/mL\] × Fasting glucose \[mg/dL\]) / 405 to assess insulin resistance. |
| Fasting glucose | Single measurement at baseline | mg/dL |
| Fasting insulin | Single measurement at baseline | µIU/mL |
Countries
Turkey (Türkiye)
Contacts
PRINCIPAL_INVESTIGATORMerve Didem Eşkin Tanrıverdi
Ankara City Hospital Bilkent
Outcome results
None listed